

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Santanu Banerjee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2106, Bethesda, MD 20892, (301) 435-5947, [banerjees5@mail.nih.gov](mailto:banerjees5@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: May 31, 2022.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-12043 Filed 6-3-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Council of Research Advocates.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

*Name of Committee:* National Cancer Institute Council of Research Advocates.

*Date:* June 29, 2022.

*Time:* 12:00 p.m. to 4:00 p.m.

*Agenda:* Welcome and Chairman's Remarks, NCI Updates, Legislative Update, and Acting Director's Update.

*Place:* National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Amy Williams, NCI Office of Advocacy Relations, National Cancer Institute, NIH, 31 Center Drive, Building 31, Room 10A28, Bethesda, MD 20892, (301) 496-9723, [williamam@mail.nih.gov](mailto:williamam@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding

the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: NCRA: <http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS).

Dated: May 31, 2022.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-12042 Filed 6-3-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Notice of Proposed Reorganization

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Biomedical Imaging and Bioengineering (NIBIB) will host a public hearing to enable public discussion of the Institute's proposal to establish the Center for Biomedical Imaging and Technology Acceleration (βETA). The proposed reorganization aims to accelerate the development, validation, and dissemination of high-impact biomedical technologies to address urgent national and global health needs.

**DATES:** The public hearing will take place on June 29, 2022, at 2 p.m. using NIBIB's social media accounts. Any interested party may also file written comments by sending an email to [NIBIBorgchange@nih.gov](mailto:NIBIBorgchange@nih.gov) prior or during the scheduled public hearing. The statement should include the individual's name, and when applicable, professional affiliation.

**ADDRESSES:** The following email address has been established for comments on the reorganization: [NIBIBorgchange@nih.gov](mailto:NIBIBorgchange@nih.gov). The social media platforms that will be used and monitored during this hearing are:

• **Twitter:** @NIBIBgov

• **Facebook:** <https://www.facebook.com/nibibgov/>

**FOR FURTHER INFORMATION CONTACT:** Eva Kakoza, Management Analyst, National Institute of Biomedical Imaging and Bioengineering, NIH, (301) 402-4584, [NIBIBorgchange@nih.gov](mailto:NIBIBorgchange@nih.gov).

**SUPPLEMENTARY INFORMATION:** Pursuant to the NIH Reform Act of 2006 (42 U.S.C. Sec.281 (d)(4)), NIBIB will have a public hearing to discuss the proposed reorganization plans. This announcement and the public forum serve as that notice. More information can be found at <https://www.nibib.nih.gov/about-nibib/proposed-org-changes>.

**Jason M. Ford,**

*Executive Officer, National Institute of Biomedical Imaging and Biomedical Engineering, National Institutes of Health.*

[FR Doc. 2022-12073 Filed 6-3-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA DK21-012 SBIR Review.

*Date:* June 29, 2022.

*Time:* 1:00 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* NIDDK, NIH, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-594-2242, [jerkinsa@nidk.nih.gov](mailto:jerkinsa@nidk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research;